Skip to content

Study · Systematic review · 2026

16 results

Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.

Rao H, Kumar S, Ali SME, Asif HM, Kumar M, Kumar L, Raja A

Journal of diabetes and metabolic disorders20 May 2026

PMID42180166 (opens in a new tab)DOI10.1007/s40200-026-01942-3 (opens in a new tab)PepBankPUB-42180166
Publisher pagePubMedAsk about this study
Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity, cagrilintide reduced percent body weight more than placebo in a meta-analysis of randomized trials.

    In plain wordsIn adults with overweight or obesity, cagrilintide cut body weight more than placebo.

    Peptide
    Cagrilintide
    Outcome
    DecreasePercent body weight change
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference in percent body weight
    −6.08%
    cagrilintide vs placebo

    Source sentences

    Summary
    Cagrilintide significantly reduced percent body weight versus placebo (mean difference - 6.08%, 95% CI - 8.02 to - 4.14)
    1 context sentence
    Summary · context
    Eligible studies enrolled adults with overweight or obesity randomized to cagrilintide or CagriSema versus placebo and reported at least one efficacy or safety outcome.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity, cagrilintide significantly reduced absolute body weight versus placebo.

    In plain wordsIn adults with overweight or obesity, cagrilintide reduced body weight in kilograms more than placebo.

    Peptide
    Cagrilintide
    Outcome
    DecreaseAbsolute body weight change
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both interventions significantly reduced absolute body weight.
    1 context sentence
    Summary · context
    Eligible studies enrolled adults with overweight or obesity randomized to cagrilintide or CagriSema versus placebo and reported at least one efficacy or safety outcome.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity, cagrilintide alone showed modest blood pressure improvements versus placebo.

    In plain wordsIn adults with overweight or obesity, cagrilintide alone modestly improved blood pressure compared with placebo.

    Peptide
    Cagrilintide
    Outcome
    DecreaseBlood pressure
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    cagrilintide alone showed modest blood pressure improvements
    1 context sentence
    Summary · context
    Eligible studies enrolled adults with overweight or obesity randomized to cagrilintide or CagriSema versus placebo and reported at least one efficacy or safety outcome.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity, cagrilintide alone had no significant glycemic effect versus placebo.

    In plain wordsIn adults with overweight or obesity, cagrilintide alone did not significantly change blood sugar measures compared with placebo.

    Peptide
    Cagrilintide
    Outcome
    No significant changeGlycemic effect (HbA1c)
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    cagrilintide alone showed modest blood pressure improvements without significant glycemic effects
    1 context sentence
    Summary · context
    Eligible studies enrolled adults with overweight or obesity randomized to cagrilintide or CagriSema versus placebo and reported at least one efficacy or safety outcome.

Studies that did not test the peptide alone12

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 05HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity, CagriSema (cagrilintide with semaglutide) reduced percent body weight more than placebo in a meta-analysis.

    In plain wordsIn adults with overweight or obesity, the combination CagriSema cut body weight more than placebo.

    Peptide
    Cagrilintide
    Outcome
    DecreasePercent body weight change with CagriSema
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Mean difference in percent body weight
    −5.98%
    CagriSema vs placebo

    Source sentences

    Summary
    as did CagriSema (- 5.98%, 95% CI - 10.64 to - 1.32)
    1 context sentence
    Summary · context
    Eligible studies enrolled adults with overweight or obesity randomized to cagrilintide or CagriSema versus placebo and reported at least one efficacy or safety outcome.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  2. 06HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity, CagriSema (cagrilintide with semaglutide) reduced percent body weight more than placebo in a meta-analysis.

    In plain wordsIn adults with overweight or obesity, the combination CagriSema cut body weight more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreasePercent body weight change with CagriSema
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Mean difference in percent body weight
    −5.98%
    CagriSema vs placebo

    Source sentences

    Summary
    as did CagriSema (- 5.98%, 95% CI - 10.64 to - 1.32)
    1 context sentence
    Summary · context
    Eligible studies enrolled adults with overweight or obesity randomized to cagrilintide or CagriSema versus placebo and reported at least one efficacy or safety outcome.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 07HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity, CagriSema significantly reduced absolute body weight versus placebo.

    In plain wordsIn adults with overweight or obesity, the combination CagriSema reduced body weight in kilograms more than placebo.

    Peptide
    Cagrilintide
    Outcome
    DecreaseAbsolute body weight change with CagriSema
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Both interventions significantly reduced absolute body weight.
    1 context sentence
    Summary · context
    Eligible studies enrolled adults with overweight or obesity randomized to cagrilintide or CagriSema versus placebo and reported at least one efficacy or safety outcome.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  4. 08HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity, CagriSema significantly reduced absolute body weight versus placebo.

    In plain wordsIn adults with overweight or obesity, the combination CagriSema reduced body weight in kilograms more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseAbsolute body weight change with CagriSema
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Both interventions significantly reduced absolute body weight.
    1 context sentence
    Summary · context
    Eligible studies enrolled adults with overweight or obesity randomized to cagrilintide or CagriSema versus placebo and reported at least one efficacy or safety outcome.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 09HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity, CagriSema significantly reduced waist circumference versus placebo.

    In plain wordsIn adults with overweight or obesity, the combination CagriSema reduced waist size more than placebo.

    Peptide
    Cagrilintide
    Outcome
    DecreaseWaist circumference with CagriSema
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    CagriSema produced a significant reduction in waist circumference
    1 context sentence
    Summary · context
    Eligible studies enrolled adults with overweight or obesity randomized to cagrilintide or CagriSema versus placebo and reported at least one efficacy or safety outcome.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  6. 10HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity, CagriSema significantly reduced waist circumference versus placebo.

    In plain wordsIn adults with overweight or obesity, the combination CagriSema reduced waist size more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseWaist circumference with CagriSema
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    CagriSema produced a significant reduction in waist circumference
    1 context sentence
    Summary · context
    Eligible studies enrolled adults with overweight or obesity randomized to cagrilintide or CagriSema versus placebo and reported at least one efficacy or safety outcome.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  7. 11HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity, CagriSema significantly reduced HbA1c versus placebo.

    In plain wordsIn adults with overweight or obesity, the combination CagriSema lowered HbA1c, a blood sugar marker, more than placebo.

    Peptide
    Cagrilintide
    Outcome
    DecreaseHbA1c with CagriSema
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    CagriSema produced a significant reduction in waist circumference and HbA1c
    1 context sentence
    Summary · context
    Eligible studies enrolled adults with overweight or obesity randomized to cagrilintide or CagriSema versus placebo and reported at least one efficacy or safety outcome.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  8. 12HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity, CagriSema significantly reduced HbA1c versus placebo.

    In plain wordsIn adults with overweight or obesity, the combination CagriSema lowered HbA1c, a blood sugar marker, more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c with CagriSema
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    CagriSema produced a significant reduction in waist circumference and HbA1c
    1 context sentence
    Summary · context
    Eligible studies enrolled adults with overweight or obesity randomized to cagrilintide or CagriSema versus placebo and reported at least one efficacy or safety outcome.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  9. 13HumanNot a test of Cagrilintide aloneSystematic reviewSafety outcome

    In adults with overweight or obesity, overall adverse events were more frequent with pooled cagrilintide and CagriSema than with placebo.

    In plain wordsIn adults with overweight or obesity, side effects were more common with cagrilintide or CagriSema than with placebo.

    Peptide
    Cagrilintide
    Outcome
    IncreaseOverall adverse events
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Overall adverse events were more frequent with active treatment, but discontinuation rates were comparable to placebo.
    1 context sentence
    Summary · context
    Eligible studies enrolled adults with overweight or obesity randomized to cagrilintide or CagriSema versus placebo and reported at least one efficacy or safety outcome.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  10. 14HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In adults with overweight or obesity, overall adverse events were more frequent with pooled cagrilintide and CagriSema than with placebo.

    In plain wordsIn adults with overweight or obesity, side effects were more common with cagrilintide or CagriSema than with placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseOverall adverse events
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Overall adverse events were more frequent with active treatment, but discontinuation rates were comparable to placebo.
    1 context sentence
    Summary · context
    Eligible studies enrolled adults with overweight or obesity randomized to cagrilintide or CagriSema versus placebo and reported at least one efficacy or safety outcome.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  11. 15HumanNot a test of Cagrilintide aloneSystematic reviewSafety outcome

    In adults with overweight or obesity, discontinuation rates with pooled cagrilintide and CagriSema were comparable to placebo.

    In plain wordsIn adults with overweight or obesity, similar numbers stopped treatment with cagrilintide or CagriSema as with placebo.

    Peptide
    Cagrilintide
    Outcome
    No significant changeDiscontinuation
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Overall adverse events were more frequent with active treatment, but discontinuation rates were comparable to placebo.
    1 context sentence
    Summary · context
    Eligible studies enrolled adults with overweight or obesity randomized to cagrilintide or CagriSema versus placebo and reported at least one efficacy or safety outcome.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  12. 16HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In adults with overweight or obesity, discontinuation rates with pooled cagrilintide and CagriSema were comparable to placebo.

    In plain wordsIn adults with overweight or obesity, similar numbers stopped treatment with cagrilintide or CagriSema as with placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeDiscontinuation
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Overall adverse events were more frequent with active treatment, but discontinuation rates were comparable to placebo.
    1 context sentence
    Summary · context
    Eligible studies enrolled adults with overweight or obesity randomized to cagrilintide or CagriSema versus placebo and reported at least one efficacy or safety outcome.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.